|
|
|
|
| LEADER |
01000caa a22002652c 4500 |
| 001 |
NLM365043478 |
| 003 |
DE-627 |
| 005 |
20250305120618.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231226s2024 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2023.109854
|2 doi
|
| 028 |
5 |
2 |
|a pubmed25n1216.xml
|
| 035 |
|
|
|a (DE-627)NLM365043478
|
| 035 |
|
|
|a (NLM)38013164
|
| 035 |
|
|
|a (PII)S1521-6616(23)00618-6
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Ameratunga, Rohan
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Challenges for gene editing in common variable immunodeficiency disorders
|b Current and future prospects
|
| 264 |
|
1 |
|c 2024
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 02.01.2024
|
| 500 |
|
|
|a Date Revised 10.04.2024
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2023 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a The original CRISPR Cas9 gene editing system and subsequent innovations offers unprecedented opportunities to correct severe genetic defects including those causing Primary Immunodeficiencies (PIDs). Common Variable Immunodeficiency Disorders (CVID) are the most frequent symptomatic PID in adults and children. Unlike many other PIDs, patients meeting CVID criteria do not have a definable genetic defect and cannot be considered to have an inborn error of immunity (IEI). Patients with a CVID phenotype carrying a causative mutation are deemed to have a CVID-like disorder consequent to an IEI. Patients from consanguineous families often have highly penetrant early-onset autosomal recessive forms of CVID-like disorders. Individuals from non-consanguineous families may have autosomal dominant CVID-like disorders with variable penetrance and expressivity. This essay explores the potential clinical utility as well as the current limitations and risks of gene editing including collateral genotoxicity. In the immediate future the main application of this technology is likely to be the in vitro investigation of epigenetic and polygenic mechanisms, which are likely to underlie many cases of CVID and CVID-like disorders. In the longer-term, the CRISPR Cas9 system and other gene-based therapies could be utilized to treat CVID-like disorders, where the underlying IEI is known
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Review
|
| 650 |
|
4 |
|a CRISPR Cas9
|
| 650 |
|
4 |
|a CVID
|
| 650 |
|
4 |
|a CVID-like disorders
|
| 650 |
|
4 |
|a Gene editing
|
| 650 |
|
4 |
|a Genotoxicity
|
| 700 |
1 |
|
|a Leung, Euphemia
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Woon, See-Tarn
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Lea, Edward
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Allan, Caroline
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Chan, Lydia
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Longhurst, Hilary
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Steele, Richard
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Snell, Russell
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Lehnert, Klaus
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 258(2024) vom: 09. Jan., Seite 109854
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnas
|
| 773 |
1 |
8 |
|g volume:258
|g year:2024
|g day:09
|g month:01
|g pages:109854
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2023.109854
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 258
|j 2024
|b 09
|c 01
|h 109854
|